Citations

Clear

626 citation(s) found for "Mehta, SH".

Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
Johnstone, Jennie , Meade, Maureen O. , Lauzier, François, Duan, Erick , Dionne, Joanna C. , Heels‐Ansdell, Diane , Thabane, Lehana , Lamarche, Daphnée , Zytaruk, Nicole , Mehta, Sangeeta , Dodek, Peter , McIntyre, Lauralyn , Karachi, Tim , Henderson, William R. , Wood, Gordon , Ovakim, Daniel , Herridge, Margaret S. , Granton, John , Wilcox, M. Elizabeth , Goffi, Alberto , Niven, Daniel J. , Lamontagne, François , D’Aragon, Frédérick , St.-Arnaud, Charles, Ball, Ian, Nagpal, Dave , Girard, Martin , Aslanian, Pierre, Charbonney, Emmanuel , Sligl, Wendy , Adhikari, Neill K. J. , Marquis, François, Archambault, Patrick , Khwaja, Kosar , Kristof, Arnold S. , Kutsogiannis, James, Paunovic, Bojan, Reeve, Brenda , Lellouche, François , Hosek, Paul, Tsang, Jennifer , Binnie, Alexandra , Trop, Sébastien, Loubani, Osama , Hall, Richard , Cirone, Robert, Reynolds, Steve, Lysecki, Paul, Golan, Eyal, Cartin‐Ceba, Rodrigo , Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Wallace, Christine, Sobhi, Gita, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Centoanti, John, Lamarche, Daphne, Laupacis, Andreas, Roberts, Robin, Brun‐Buisson, Christian , Reynolds, Steve, Willems, Sue, Sekhon, Tina , Dodek, Peter, Ayas, Najib , Agda, Maria, Alcuaz, Victoria, Ashley, Betty-Jean, Brewer, Kelsey, Palmer, Janice L. , Brown, Glen, Pavan, Mara, Greisdale, Donald, Foster, Denise , Logie, Suzie, Yip, Judy, Auld, F. C., Carney, Gayle, FLEMING, R.Y. Declan, Good, Jennifer, Manhas, Mandeep, Boyd, Karin, Dheere, Jane, Stelfox, Tom, Couillard, Philippe , Doig, Christopher J. , Booth, Joshua , Codan, Cassidy, Ruddell, Stacy, Cameron, C. Blake, Edison, Rhonda, Mina, Breanna, Berthiaume, Luc , Gaudet, Jonathan, Kutsiogiannis, Jim, Chowdhury, Raiyan, Davidow, Jon, Johnston, Curt, Johnston, Richard , Macala, Kim, Marcushamer, Sam, Markland, D., Matheson, Doug, Payton-Gay, Damian, Zygun, David, Hewer, Tayne, Thompson, Pat, Ge, Maggie, Hall, Janny, Matenchuk, Sharon, Baig, Nadia, McCoshen, Lorena, Alexandropoulos, Katrina, Bain, Sherri, Brandt, Michelle , Constable, Cathy, Douglas, K., Maharaj, Shaleen, Travers, Sabrina, Zarychanski, Ryan, Lys, Justin, Marten, Nicole, Bhairo, Audrey, Ferenes, Halyna, Kozak, Beata, Verrier, Debra, McLaughlin, Dawn-Lee, Blouw, Marcus , Smith, Heather , Gutieror, Oliver, Wingfield, Sherri Lynn, Boyle, M A, Hrabi, Debbie, MacDonald, Chantal, Bento, Karen, Davis, Megan , Dechert, William , Longo, Barbara, Mullen, Courtney, Skrzpek, Elysia, Wierenga, Laurenne, Abuzaiter, Wesam, Amorim, Lynda, Bauer, Rosemarie, Damota, Rachel, Ho, Hoang, Macdougall, Nicole, Thornewell, Mary, Tran, Lara , Visocchi, Jennifer, Hosek, Paul, Plaxton, Bill, Armstong, Catherine, Ellis, Janelle, Fisk, Kayla, Gabnouri, Melissa, Gordon, Emilie, Haegens, Rebecca, Halford, Lisa, Hillis, Brooklyn, Jesso, Rebecca, McLaren, Jennifer , McMillan, Elliot, Pelkmans, Mariska, Rekman, Matthew, Sinkovitis, Sylvia, Truong, Monica, White, Michelle C. , Bates, Noah, Bryden-Cromwell, Susan, Cameron, Colleen, Deen, A. Gamal El, DiGiovanni, Sheri, Foss, Anders, Lee, E. H. , MacGregor, Heidi, Galbraith, Esther, McArthur, Robyn, Mcgregor, J., Miller, Keith R. , Morris, Sharon, Parker, Shelley, Smith, Candice A. , Stoglow, Joanna, Tung, Jennifer , Vos, Melissa , Hand, Lori, Klotz, Lisa, Sabev, Alexandra, Savija, Nevena , Guyatt, Paige, Cosentino, Deanna, Lourenco, Diane, Misina, Julie, Berlingieri, Joseph, Skitch, Steven , Campbell, Tracy , Basheer, Hala, Bruder, Kathy, Cheng, Jane, Qureshi, Kaiser, Infantino, C. A. González, Karachi, Timothy, Alghuroba, Mashari, Khaled, Alia , Millen, Tina, Vaisler, Ryan, Biljan, Maya, Cosentino, Deane, Marriott, Brittany, Muscedere, John, Boyd, Gordon, D`Arsigny, Christine, Drover, John, Erb, Jason , Parker, Chris M., Sibley, Stephanie , Boyd, Tracy, Georgescu, Ilinca, Hunt, Miranda , Muscedere, D., Baker, Cathy, Engel, Jennifer, Fleming, Jennifer , Roderick, Lisa, Silk, Shelley, Spencer, Marcy, Tryon, Michelle, Nagpal, Dave, Ball, Ian, Sharpe, Michael D., Bentall, Tracey, Sturt-Smith, Jessica, Ellis, T.M., Muylaert, Mindy, Paczkowski, Cindy, Campbell, Eileen, Imervoski, Susie, Ovsenek, Athena, Rondinelli, Rebecca, Longfield, Teresa, Moyer, Amy, Norris, F. H., Sumpton, Janice, Teterycz, Karina, Lapinsky, Stephen E. , Munshi, Laveena, Brown, Maedean, Giacomino, Brittany, Jakab, Marnie, Kraguiljac, Alan, Shah, Sumesh, Tamberg, E., Cheng, Doret, Han, Andrew , Leung, Holly, Mantas, Ioanna, Rodrigues, Hilary, Wyllie, Andew, Carmargo, Mercedes, Richter, Beverly, Caporuscio, Rita, Falvo, Rachel Kressner, Fleming, Dimitra, Maxwell, Carmelina, Plantic, Karmen, McIntyre, Lauralyn, Pagliarello, Giuseppe, D`Egidio, Gianni, English, Shane, Hartwick, Mike, Hooper, Jonathan C., Kubelik, D., Meggison, Hilary , Patel, Rakesh , Po, Joseph, Rosenberg, Erin, Gomes, Brigette, Leclair, Lianne, Porteous, Rebecca , Reddie, Shawna, Watpool, Irene , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, Richard, Susanne, Weir, Sherry, Cardinal, Pierre , Jones, Gwynne, Microys, Sherissa, Sarti, Aimee , Seely, Andrew , Acres, Shelley, Mietitis, Sydney, Montroy, Kaitlyn, Aikens, Wendy, Dugal, Anne-Marie, Soth, Mark, Alhazanni, Waleed, Clarke, France, Copland, Mary, Hoad, Neala, Sheers, M., Takaoka, Alyson, Zytaruk, Nicole, Connolly, Christa, Davis, Denise, Gallinas, Tracy, Lee-Yoo, Jean, Lukinuk, Connie, Musielak, Leia, Pavunkovic, Nancy, Pelayo, Joy, Phillips, Kaitlyn , Pracsovics, Catherine, Raimondo, Julia, Stankus, Vida, Wright, Angela, Young, Crystal , Cirrone, Rob, Kavikondala, Kanthi, Pellerin, Axelle, Tomat, Laura, Carter, Jeff , Jani, J., Yaets, Brendan, Hodder, Jennifer, Khalid, Imrana, Lee, Julie , Salway, Kurtis D., Sandhu, Gyan, Santos, Marlene, Smith, Orla, Wang, Melissa, Dewhurst, Norman, Dowbenka, Ann, Kosinski, Ann, Parsons, Laura, Proceviat, J, Ramonas, Gitana, Yuen, Mae, Amaral, Andre , Fowler, Rob, Scales, Damon C. , Marinoff, Nicole, Pérez, Adic, Wang, Jane , Hatzifilalithis, Katrina, Iazzetta, John, Kolos, Chrys, Quinton, Ingrid, Herridge, Margaret, Archer, Jaimie, Fraser, Brooke , Geen-Smith, Cheryl, Matté, Andrea, Robles, Priscilla, Urrea, Cristian, Ascroft, Jane, Haji, Fatima , Ming, Jie , Suen, Matthew , Walid, Muhammad, Westlund, Jill M., McCredie, Victoria , Wilcox, Elizabeth , Farías, Paulina , Kosky, Barbara, Pugliese, Christina, Stenyk, Lia, Walczak, Karolina, Ae, Kyung, Kaur, Rajvinder , Lui, Jane , Mateo, Sophia, Pham, Nga, Heslegrave, Ronald J. , Panchbhaya, Zaynab, Sharman, Kim, Goel, Rakhi, Kozluk, Kim, Labelle, Julianne, Marsonia, Hina, Scott, Cecillia, Aslanian, P., Bélisle, Sylvain, Denault, André , Guimond, Jean‐Gilles, Halwagi, Antoine, Hebert, Paul L. , Kolan, Christopher, Mancebo, Jordi , Robillard, Nicholas , Benettaib, Fatna, Boumahni, Dounia, Caporuscio, Casey Bourdeau, Cantin, M, Côté-Gravel, Virginy, Ghamraoui, Ali, Lebrasseur, Martine, Courville, Lancelot Legendre, Lorio, S., Madrid, Maria Trinidad, Poitras, Nicole, Rigal, Romain, Salamé, Maya, Tran, V.K., Bacon, Katie, Boudreau, Nathalie , Carvajal, Cecilia, Gauthier, Lyne, Gendron, Julie, Jean, Karine, Laforest, Louise, Lembo, Antonietta, Lim, S. H., Pagé, France, Pelletier, L, Rodrigue, Marie-Christine, Bellemare, Jean-François, Bordeleau, Simon, Drouin, Christine, Duhaime, Benoit, Laberge, Ann, Lechance, Philippe, Deblois, Estel, Dionne, Maude, Lavoie, Lise, Michel, Isabelle, Pépin, A., Poulin, S., Anctil, Sarah, Marchand, Louis-Étienne , Roy, Robin, St-Arnaud, Charles , Quiroz, Héctor, Bérard, Dominique, Leclair, Marc-André, Bolduc, Virginie, Carbonneau, Élaine, Marchand, Joannie, Masse, Marie-Hélène , Cloutier, Sylvie , Guay, M, Morin, Line, Nicolson, J. T., Paquette, Isabelle, Théberge, France, Lamarche, Yoan , LeGuillan, Soazig, Serri, Karim , Verdant, Colin , Beaulieu, Yanick, Bellemare, Patrick, Rico, Philippe, Bernard, Françis , Giasson, Marc, Brunette, Véronique, Cavayas, Alexandros, Lévesque, Émilie, Labikova, Halina, Palacios, Julia , Langlois, Marie-Ève, Williams, Virginie, Nguyễn, Thùy Anh , Phaneuf, Valérie, Wang, Han Tin, Toupin, Francis, Ahern, Stéphane P., Laufer, Brian, Brosseau, Marc, Dul, Pauline, Harvey, Johanne, Inthanavong, Lotthida, Tassy, Danaë, Assayag, Helen, Bachand, M., Bétournay, Marysa, Daoust, Karine, Goyette, Kristine, Lessard, Ariane, Quach, Marceline, Barriault, Danny, Bellemare, David, Boivin, Anick, Breton, S., Cloutier, Ève, Daigle, Marjorie, Delisle-Thibeault, Charles, Giannakouros, Panagiota, Grenier, Stéphanie, Guilbault, Gabrielle, Léger, Caroline, Trembley, Marie-Claude, Gaudreau, Julie, Grégoire, Claire, Labbé, Véronique, Laprise-Rochette, Ariane, Ouellet, Caroline, Samson, Mélanie , Simoneau, Marie-David, Tourcotte, Virginie, Tran, Tuong-Vi, Lellouche, François, Sia, Ying Tung, Simon, Mathieu, Bouchard, Pierre-Alexandre, Lizotte, Patricia, Châteauvert, Nathalie, Grenier, T, Khwaja, Kosar, Deckelbaum, Dan, Gursahaney, Ash, Hornstein, David, Jayaraman, Dev , Razek, Tarek , Salasidis, Robert, Zanelli, Patrizia, Alam, Norine , Doerksen, Tonia, Matte, Gilbert, Robert, Marie‐France, Goldberg, Peter, Hatzakorzian, Roupen , Shahin, Jason , Qureshi, Salman, Campisi, Josie, Botan, Vasilica, Capilnean, Anissa, Corey, A. E., Gagné, Annick, Mian, J N, Normandin, Kathleen, Hall, Rick , Green, Robert, Gillis, Diana, Julien, Lisa, Magennis, Laura, Mitterer, Tamara, Arsenault, Joanna, Bruce-Payne, Kim, Gallant, Patti, Oeckler, Richard A. , Anderson, Brenda J., Liedl, Lavonne M., Meade, Laurie, Weist, Sueanne, Bartoo, Anna, Bauer, Debbie, Brickley, Vince, Bridges, S. Louis , Brunn, G.J., Eickstaedt, Jennifer E., Bergerson, Jill, Showalter, Sandy, Manley, Melissa, Taylor, Robert, Cryton, Margaret, Fowler, K. T., Krause, Katie, O`Brien, Jackie, Tow, Marianne, Ma, John, Moore, Kaitlin MS, Al‐Dawood, Abdulaziz, Tlayjeh, Haytham , Ghanem, Alaaeldien, Hassanien, Ahmad, Sharkawi, Ashraf El, Humaid, Felwa Bin, Alanizi, Hala, Alanizy, Nadyah, Bogami, Njoud Al, Muhaidib, Mohammed, Gramish, Jawaher , Alsomali, Randa, Devera, Nora, Villafranca, M.C. Muñoz, Fowler, Robert , Thabane, Lehana , Lauzier, François, Marshall, John C. , Arabi, Yaseen M. , Surette, M G , English, Shane , Rochwerg, Bram , Stelfox, Henry T. , Muscedere, John , Ball, Ian, Williamson, David R. , Friedrich, Jan O. , Kutsogiannis, Demetrios James , Zarychanski, Ryan , Taylor, Robert, Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Oczkowski, Simon J. W. , Bowdish, Dawn M. E. , Reynolds, Steve, Dodek, Peter, Ashley, Betty Jean, Palmer, Janice, Sekhon, Mypinder S. , Auld, Fiona, Fleming, R.Y.Declan, Stelfox, Tom, Parhar, Ken Kuljit S. , Cameron, Candice, Martin, Anne , Thompson, Pat, Bagshaw, Sean M. , Brandt, Michelle, Douglas, Kari, Zarychanski, Ryan, Valente, Maria, Olafson, Kendiss P. , Smith, Heather, Abuzaiter, Wesam, Hosek, Paul, Fisk, Kayla M., McLaren, Jennifer, White, Michelle, Deen, Aminah, Lee, Esther, McGregor, Julie, Miller, Keith, Morris, Sharon, Vos, Melissa, Belley‐Côté, Emilie P. , Shaikh, Sameer, Qureshi, Kaiser, Muscedere, John, D`Arsigny, Christine, Maslove, David M. , Fleming, Jennifer, Spencer, Marcy, Nagpal, Dave, Ball, Ian, Bosma, Karen J. , Alexander, Michelle, Norris, Faith, Munshi, Laveena , Grewal, Gagan , McIntyre, Lauralyn, D`Egidio, Gianni, English, Shane, Hooper, Jonathan, Kyeremanteng, Kwadwo , Neilipovitz, David , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, MacLeod, Rob , Rose, Dawn, Kim, John S. , Beinum, Amanda van , Fetzer, Susan, Clarke, France J. , Sheers, Melissa, Zytaruk, Nicole, Davis, Denise, Eaton, Catherine, Lukinuk, Connie, Wright, Angela, Khalid, Imrana, Lee, Julie, Lee, Yoon Min , Cuthbertson, Brian H. , Kaur, Navjot , Herridge, Margaret, Chen, Daniel Tzu-Hsuan , Haji, Fatima, Ming, Jie, Farias, Paulina, Kaur, Rajvinder, Pham, Tam Thi , Goel, Rakhi, Carrier, François Martin , Chassé, Michaël , Hébert, Paul, Kolan, Christophe , Boumahni, Dounia, Ghamraoui, Ali, Lebrasseur, Martine, Lorio, Stéphanie, Laforest, Louise, Lim, Sothun, Morrissette, Jennifer, Pagé, France, Dionne, Maude, Michel, Isabelle, Pépin, Alexandre, Poulin, Sandrine, Cloutier, Sylvie, Nicolson, Jessie, Paquette, Isabelle, Harvey, Johanne, Inthanavong, Lotthida, Daoust, Karine, Turgeon, Alexis F , Boivin, Anick, Breton, Sarah-Judith, Ouellet, Catherine, Grégoire, Claire, Samson, Mélanie, Lellouche, François, Khwaja, Kosar, Grushka, Jeremy Richard , Garcia, Laura, Magder, Sheldon A. , Corey, Alyssa, Mian, Jasmine, Hall, Rick, Green, Robert, Gillis, Diana, Anderson, Brenda, Brunn, Greg, Stern, Erin, Taylor, Robert, Fowler, Kim, Krause, Katie, Moore, Kaitlin , Ghanem, Alaaeldien, Hegazy, Mohamed I. , Villafranca, Marjane

Mayo Clinic

JAMA | September 21, 2021 | Volume: 326 | Issue: 11 | Pages: 1024

10.1001/jama.2021.13355 | PMID 34546300 Get It

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
Investigators, The Parkinson Study Group SURE-PD3, Bluett, Brent , Togasaki, Daniel M., Mihaila, Dragos, Evatt, Marian L., Rezak, Michael, Jain, Samay , Schwarzschild, Michael A. , Ascherio, Alberto, Casaceli, Cindy, Kamp, Cornelia , Lungu, Codrin , Oakes, David , Rudolph, Alice, Shoulson, Ira , Scott, B.L. , Gauger, Lisa, Aldred, Jason , Bixby, Melissa, Ciccarello, Jill, Gunzler, Steven A. , Henchcliffe, Claire , Brodsky, Matthew , Keith, Kellie, Hauser, Robert A. , LeDoux, Mark S. , Hinson, Vanessa K. , Kumar, Rajeev , Hunter, Christine , Christine, Chadwick W. , Daley, Aaron, Leehey, Maureen A. , Marcaida, Joy Antonelle de, Hung, Albert Y. , Bwala, Grace, Simon, David K. , Simuni, Tanya , Poon, Cynthia , Schiess, Mya C. , Park, Ariane , Peterson, Carolyn, Criswell, Susan R. , Durphy, Jennifer, Shill, Holly A. , Mehta, Shyamal H. , Deik, Andres , Fang, John Y., Stover, Natividad , Zhang, Lin , Dewey, Richard B. , Gerald, Ashley, Boyd, James T. , Houston, Emily , Suski, Valerie, Mosovsky, Sherri, Cloud, Leslie , Shah, Binit, James, Raymond , Zauber, S. Elizabeth , Reich, Stephen G. , Langhammer, April, LaFaver, Kathrin , Kaminski, Patricia L. , Goudreau, John L. , Russell, Doozie, Houghton, David , LaRoche, Ashley , Thomas, Karen , McGraw, Martha, Mari, Zoltan, Blindauer, Karen, Rabin, Marcie, Kurlan, Roger, Morgan, John C. , Ainslie, Melissa, Bódis-Wollner, Iván , Waters, Cheryl , Ratel, Amber Servi, Beck, Christopher A. , Bolger, Patrick, Callahan, Katherine F., Crotty, Grace F. , Klements, David , Kostrzebski, Melissa, McMahon, Gearoid M. , Pothier, Lindsay , Hauser, Robert A , Simuni, Tanya , Investigators, The Parkinson Study Group SURE-PD3, Curhan, Gary C. , Fitzgerald, Rebecca, Macklin, Eric A. , Marek, Kenneth , Mozaffarian, Dariush , Videnovic, Aleksandar , Goetz, Christopher G. , Espay, Alberto J. , Jimenez‐Shahed, Joohi , Friedman, Joseph H. , Litvan, Irene , Chou, Kelvin L. , Bhatti, Danish , Rosenthal, Liana S. , Ahmed, Anwar E. , Saint‐Hilaire, Marie , Shprecher, David , Pahwa, Rajesh , LeWitt, Peter A. , Kaminski, Patricia, Thomas, Karen, Serrano, Carmen , Soileau, Michael J , Schneider, Ruth B. , Waikar, Sushrut S. , Lang, Anthony E. , Mestre, Tiago

Mayo Clinic

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802 Get It

Role of infectious diseases pharmacists in outpatient intravenous and complex oral antimicrobial therapy: Society of Infectious Diseases Pharmacists insights
Rivera, Christina G. , Mehta, Meera, Ryan, Keenan , Tucker, Kendall J , Ryan, Keenan L , Rivera, Christina G , Stevens, Ryan W. , Mahoney, Monica V.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | September 8, 2021 | Volume: 4 | Issue: 9 | Pages: 1161-1169

10.1002/jac5.1473 Get It

AbstractOutpatient parenteral antimicrobial therapy (OPAT) is a well‐established mechanism to facilitate patient discharge, lower inpatient admission cost, and decrease the risk of health care–acquired infections. Although there are numerous benefits to patients and health care institutions, OPAT is complex and not without risks. Patients may be discharged on long courses of oral antimicrobials, known as complex outpatient antimicrobial therapy (COpAT), which also requires careful monitoring and oversight. This, coupled with the need for antimicrobial stewardship across the continuum of care, positions pharmacists with infectious diseases (ID) training as crucial leaders in the field of OPAT. The development, implementation, and maintenance of these services requires the careful attention of health care personnel in discharge antimicrobial selection, continuity of care at key care transitions, implementation of optimal care bundles, provision of thorough patient education throughout the OPAT process, coordination with a multidisciplinary team including home infusion and nursing, and monitoring of program metrics to determine successes and opportunities for improvement. Ongoing support for optimal delivery of patient care will be required as OPAT practice, and health care delivery at large, continues to evolve. This involves continued advocacy for collaborative practice development, optimizing payment for nondispensatory OPAT services, and integration of effective telehealth programs. This article summarizes the need for practice expansion of ID pharmacist specialists in OPAT/COpAT management across the care continuum and best practices for establishment of these services.
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma
Fleming, Jessica L. , Pugh, Stephanie L. , Fisher, Barbara J., Lesser, Glenn J. , Macdonald, David R., Bell, Erica H. , McElroy, Joseph , Becker, Aline Paixão , Timmers, Cynthia , Aldape, Kenneth , Rogers, Leland , Doyle, Thomas J. , Werner‐Wasik, Maria, Bahary, Jean-Paul , Tsai, Ya-Yu , D’Souza, David , Sneed, Penny K. , Kwok, Young , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

JCO Precision Oncology | September 1, 2021 | Volume: No volume available | Issue: 5 | Pages: 1397-1407

10.1200/po.21.00112 | PMID 34589661 Get It

PURPOSE This study sought to determine the prognostic significance of the WHO-defined glioma molecular subgroups along with additional alterations, including MGMT promoter methylation and mutations in ATRX, CIC, FUBP1, TERT, and TP53, in NRG/RTOG 0424 using long-term follow-up data. METHODS Mutations were determined using an Ion Torrent sequencing panel. 1p/19q co-deletion and MGMT promoter methylation were determined by Affymetrix OncoScan and Illumina 450K arrays. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and tested using the log-rank test. Hazard ratios were calculated using the Cox proportional hazard model. Multivariable analyses (MVAs) included patient pretreatment characteristics. RESULTS We obtained complete molecular data to categorize 80/129 eligible patients within the WHO subgroups. Of these, 26 (32.5%) were IDHmutant/co-deleted, 28 (35%) were IDHmutant/non-co-deleted, and 26 (32.5%) were IDHwild-type. Upon single-marker MVA, both IDHmutant subgroups were associated with significantly better OS and PFS ( P values < .001), compared with the IDHwild-type subgroup. MGMT promoter methylation was obtained on 76 patients, where 58 (76%) were methylated and 18 (24%) were unmethylated. Single-marker MVAs demonstrated that MGMT promoter methylation was statistically significant for OS ( P value < .001) and PFS ( P value = .003). In a multimarker MVA, one WHO subgroup comparison ( IDHmutant/co-deleted v IDHwild-type) was significant for OS ( P value = .045), whereas MGMT methylation did not retain significance. CONCLUSION This study reports the long-term prognostic effect of the WHO molecular subgroups, MGMT promoter methylation, and other mutations in NRG/RTOG 0424. These results demonstrate that the WHO molecular classification and MGMT both serve as strong prognostic indicators, but that MGMT does not appear to add statistically significant prognostic value to the WHO subgrouping, above and beyond IDH and 1p/19q status.
Endoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study
Pérez, Lady Katherine Mejía , Draganov, Peter V. , Jawaid, Salmaan , Chak, Amitabh , Dumot, John A. , Alaber, Omar , Jang, Sunguk , Mehta, Neal , Chua, Tiffany , Gabr, Moamen , Kudaravalli, Praneeth , Aihara, Hiroyuki , Ngamruengphong, Saowanee , Khoshknab, Milad Pourmousavi, Bhatt, Amit , Mejia Perez, Lady Katherine , Alaber, Omar , Fukami, Norio , Maluf-Filho, Fauze , Bhatt, Amit , Yang, Dennis J. , Vargo, John Joseph , Fukami, Norio

Mayo Clinic

Endoscopy | August 27, 2021 | Volume: 54 | Issue: 05 | Pages: 439-446

10.1055/a-1541-7659 | PMID 34450667 Get It

Abstract Background The difference in clinical outcomes after endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early Barrett's esophagus (BE) neoplasia remains unclear. We compared the recurrence/residual tissue rates, resection outcomes, and adverse events after ESD and EMR for early BE neoplasia. Methods We included patients who underwent EMR or ESD for BE-associated high grade dysplasia (HGD) or T1a esophageal adenocarcinoma (EAC) at eight academic hospitals. We compared demographic, procedural, and histologic characteristics, and follow-up data. A time-to-event analysis was performed to evaluate recurrence/residual disease and a Kaplan–Meier curve was used to compare the groups. Results 243 patients (150 EMR; 93 ESD) were included. EMR had lower en bloc (43 % vs. 89 %; P < 0.001) and R0 (56 % vs. 73 %; P = 0.01) rates than ESD. There was no difference in the rates of perforation (0.7 % vs. 0; P > 0.99), early bleeding (0.7 % vs. 1 %; P > 0.99), delayed bleeding (3.3 % vs. 2.1 %; P = 0.71), and stricture (10 % vs. 16 %; P = 0.16) between EMR and ESD. Patients with non-curative resections who underwent further therapy were excluded from the recurrence analysis. Recurrent/residual disease was 31.4 % [44/140] for EMR and 3.5 % [3/85] for ESD during a median (interquartile range) follow-up of 15.5 (6.75–30) and 8 (2–18) months, respectively. Recurrence-/residual disease-free survival was significantly higher in the ESD group. More patients required additional endoscopic resection procedures to treat recurrent/residual disease after EMR (EMR 24.2 % vs. ESD 3.5 %; P < 0.001). Conclusions ESD is safe and results in more definitive treatment of early BE neoplasia, with significantly lower recurrence/residual disease rates and less need for repeat endoscopic treatments than with EMR.
Impact of Adjunctive Pharmacotherapy With Intragastric Balloons for the Treatment of Obesity
Mehta, Amit , Shah, Shawn L. , Dawod, Enad , Hajifathalian, Kaveh , Kumar, Rekha B. , Igel, Leon I. , Saunders, Katherine H. , Kumbhari, Vivek , Farha, Jad , Badurdeen, Dilhana, Itani, Mohamad I. , Moore, Rachel , Starpoli, Anthony A., Carr‐Locke, David L. , Shukla, Alpana P. , Aronne, Louis J. , Sharaiha, Reem Z.

Mayo Clinic

The American Surgeon™ | August 12, 2021 | Volume: 89 | Issue: 4 | Pages: 707-713

10.1177/00031348211038579 | PMID 34384255 Get It

Background We conducted this study to compare the weight loss outcome of intragastric balloons (IGBs) in conjunction with pharmacotherapy vs IGB and intensive lifestyle changes alone. Methods This was a multicenter, non-randomized, retrospective study involving 4 academic hospitals. Patients underwent IGB placement with or without concomitant anti-obesity pharmacotherapy. The primary outcome was percent total weight loss (TBWL) after IGB placement at 6 and 12 months. Results This study included 102 patients, with 23 patients (mean age 46.6 years, 82.6% female) treated with IGB/pharmacotherapy and 79 patients (mean age 46.0 years, 88.6% female) treated with IGB/lifestyle modifications. Patients had a 100% follow-up rate at 6 and 12 months. At 6 months following IGB placement, both groups achieved a similar %TBWL. At 12 months, %TBWL was greater in the IGB/pharmacotherapy group (12.6% ± 1.2 vs 9.7% ± 0.7, P = .04). 65.2% of patients achieved ≥10% TBWL at 12 months in the IGB/pharmacotherapy group, compared to 38.0% in the IGB/lifestyle group ( P < .05). The proportion of patients that achieved ≥15% weight loss at 12 months was also significantly different between the IGB/pharmacotherapy and IGB/lifestyle groups (30.4% vs 20.3%, P < .05). Discussion IGB with concomitant use of pharmacotherapy did not improve weight loss while the IGB was in place compared to IGB and lifestyle changes. However, patients receiving IGB with pharmacotherapy did have greater weight loss and diminished weight regain after balloon removal compared to those receiving just IGB and lifestyle changes.
Heart failure in pregnancy: what is the long-term impact of pregnancy on cardiac function? A tertiary care centre experience and systematic review
Dodeja, Anudeep K. , Siegel, Francesca, Dodd, Katherine, Ma’ayeh, Marwan , Fuchs, Margaret , Mah, May Ling , Bradley, Elisa A. , Fuchs, Margaret M , Bradley, Elisa A , Mehta, Laxmi S. , Rood, Kara M.

Mayo Clinic

Open Heart | August 3, 2021 | Volume: 8 | Issue: 2 | Pages: e001587

10.1136/openhrt-2021-001587 | PMID 34344721 Get It

Background Women with cardiomyopathy (CM) are often advised against pregnancy due to risk for major adverse cardiovascular events (MACE). However, the impact of CM subtype on maternal MACE is not understood, and so we sought to evaluate the influence of CM phenotype on maternal outcomes, as well as the effect on immediate and late left ventricular function. Methods We evaluated all pregnant women in our high-risk maternal cardiovascular programme (2009–2019). Composite maternal MACE included: death, inotrope use, left ventricular assist device, orthotopic heart transplant and/or escalation in transplant listing status, acute decompensated heart failure and sustained ventricular arrhythmia. Results Among 875 women followed, 32 had CM (29±7 years old, left ventricular ejection fraction (LVEF) 41%±12%): 3 ischaemic CM (ICM), 10 peripartum CM (PPCM) and 19 non-ICM (NICM). MACE events occurred in 6 (18%) women (PPCM: 2 (33%), NICM: 4 (67%)). There was no difference in LVEF at baseline, however, women with MACE had significantly lower LVEF both early (LVEF: 27±5% vs . 41±2%, p<0.05) and late post partum (LVEF: 28±5% vs . 44±2%, p<0.01). Conclusions In this contemporary cohort of women with CM, maternal MACE rates were lower than previously reported, and were less common in PPCM as compared with ICM and NICM. Heart function in women with MACE was negatively impacted immediately after delivery and in late postpartum follow-up, suggesting that pregnancy itself likely has influence on future left ventricular function in women with underlying CM.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
Wen, Patrick Y. , Lim, Michael , Platten, Michael , Colman, Howard , Ashley, David M. , Chang, Susan M. , Mansouri, Alireza , Khagi, Simon , Heimberger, Amy B. , Reardon, David A. , Sahebjam, Solmaz , Simes, John, Antonia, Scott , Berry, Don, Tan, Aaron C. , Platten, Michael , Heimberger, Amy B. , Khasraw, Mustafa , Mansouri, Alireza , Bagley, Stephen , Wen, Patrick Yung , Colman, Howard , Wick, Wolfgang , Chang, Susan Marina , Galanis, Evanthia , Mehta, Minesh P. , Puduvalli, Vinay K. , Simes, Robert John , Berry, Donald A. , Khasraw, Mustafa

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 2, 2021 | Volume: 9 | Issue: 7 | Pages: e002459

10.1136/jitc-2021-002459 | PMID 34215688 Get It

With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel–novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the most difficult questions in medical research. We conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review of trials of novel–novel combination therapies involving immunotherapies or molecular targeted therapies in advanced solid tumors. A MEDLINE search was conducted using a modified Cochrane Highly Sensitive Search Strategy for published clinical trials between July 1, 2017, and June 30, 2020, in the top-ranked medical and oncology journals. Trials were evaluated according to a criterion adapted from previously published Food and Drug Administration guidance and other key considerations in designing trials of combinations. This included the presence of a strong biological rationale, the use of a new established or emerging predictive biomarker prospectively incorporated into the clinical trial design, appropriate comparator arms of monotherapy or supportive external data sources and a primary endpoint demonstrating a clinically meaningful benefit. Of 32 identified trials, there were 11 (34%) trials of the novel–novel combination of anti-programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) therapy, and 10 (31%) trials of anti-PD-1/PD-L1 and anti-vascular endothelial growth factor (VEGF) combination therapy. 20 (62.5%) trials were phase II trials, while 12 (37.5%) were phase III trials. Most (72%) trials lacked significant preclinical evidence supporting the development of the combination in the given indication. A majority of trials (69%) were conducted in biomarker unselected populations or used pre-existing biomarkers within the given indication for patient selection. Most studies (66%) were considered to have appropriate comparator arms or had supportive external data sources such as prior studies of monotherapy. All studies were evaluated as selecting a clinically meaningful primary endpoint. In conclusion, designing trials to evaluate novel–novel combination therapies presents numerous challenges to demonstrate efficacy in a comprehensive manner. A greater understanding of biological rationale for combinations and incorporating predictive biomarkers may improve effective evaluation of combination therapies. Innovative statistical methods and increasing use of external data to support combination approaches are potential strategies that may improve the efficiency of trial design. Designing trials to evaluate novel–novel combination therapies presents numerous challenges to demonstrate efficacy in a comprehensive manner. A greater understanding of biological rationale for combinations and incorporating predictive biomarkers may improve effective evaluation of combination therapies. Innovative statistical methods and increasing use of external data to support combination approaches are potential strategies that may improve the efficiency of trial design.
FXR Promotes Endothelial Cell Motility through Reciprocal Regulation of FAK and MMP‐9
Yaqoob, Usman , Mehta, Dolly , Shah, Vijay H. , Das, Amitava , Yaqoob, Usman

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.634.9 Get It

Farnesoid X Receptor (FXR) mediates important signaling functions of bile acids in diverse cell types including those residing in the vascular wall. Indeed, recent work has identified FXR as a potential regulator of vascular structure and function in part through transcriptional activation of MMP‐9. However, the signal transduction pathways linking bile acids to changes in actin cytoskeleton that are responsible for bile acid induced vascular cell migration remain unexplored. The FXR agonist and prototypical bile acid, chenodeoxycholic acid (CDCA), significantly increased endothelial cell (EC) motility, as analyzed by time lapse video microscopy, and tube formation, an in vitro correlate for angiogenesis. Increased cell motility was associated with prominent increases in focal adhesion (FA) plaques and was inhibited by FXR or MMP‐9 siRNA, indicating a FXR‐MMP‐9‐dependency of this signaling pathway. Mechanistically, incubation of cells with CDCA was associated with phosphorylation of a key FA protein, Focal Adhesion Kinase (FAK) at Y397 but not at Y576/577, or Y925. Studies using a site‐specific phosphodefective FAK mutant revealed that FAK phosphorylation at tyrosine residue ‐397 was required for CDCA induced activation of the downstream FA assembly protein, paxillin. Lastly, siRNA based silencing of FAK as well as phosphodefective FAK mutant both inhibited CDCA induced upregulation of MMP‐9, cell motility and tube formation. Thus, this study demonstrates a pivotal role for FAK in the process of FXR‐induced and MMP‐9 ‐dependent EC motility and vascular tube formation. Funded by NIH Grant # DK059615